ALK and neoplasm: With the development of tumor-related small-molecule targeted therapy, a second-generation ALK-TKI alectinib significantly increased the median PFS (25.7 vs. 10.4 months) than crizotinib in the first-line treatment of ALK-positive NSCLC (Mok et al., 2020).